Who
Nicole Sweeny
Director
Company insider
Files Form 4 as: Director, Monopar Therapeutics; Chief Commercial Officer, KalVista Pharmaceuticals; Chief Commercial Officer, Praxis Precision Medicines.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $474K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 12 Feb 2021
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,284 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,284 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —59,291 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —100,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —68,750 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —93,750 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —68,750 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —93,750 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticals | SEC FORM 4 Code D | —59,291 at $0.00 | filing |
| 26 May 2026filed 27 May 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $40K1,489 at $26.78 | filing |
| 26 May 2026filed 27 May 2026 | KalVista Pharmaceuticals | SEC FORM 4 Sold | $40K1,489 at $26.78 | filing |
| 22 May 2026filed 27 May 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —5,000 | filing |
| 22 May 2026filed 27 May 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | KalVista Pharmaceuticals | SEC FORM 4 Code M | —5,000 | filing |
| 22 May 2026filed 26 May 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $50K1,861 at $26.78 | filing |
| 22 May 2026filed 26 May 2026 | KalVista Pharmaceuticals | SEC FORM 4 Sold | $50K1,861 at $26.78 | filing |
News
No headline names them, or the companies they trade most, lately.